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Abstract
The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment.
Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tumor-associated
antigens (TAAs) expressing on tumor cell surface. Current studies demonstrated that various TAAs could act as
target antigens for CAR-T cells, for instance, the type III variant epidermal growth factor receptor (EGFRvIII) was
considered as an ideal target for its aberrant expression on the cell surface of several tumor types. CAR-T cell
therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid
tumor as showed in various clinical trials. The third generation of CAR-T demonstrates increased antitumor
cytotoxicity and persistence through modification of CAR structure. In this review, we summarized the preclinical
and clinical progress of CAR-T cells targeting EGFR, human epidermal growth factor receptor 2 (HER2), and
mesothelin (MSLN), as well as the challenges for CAR-T cell therapy.
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Background
Over a century, immunology has been employed to treat
malignant tumors, such as monoclonal antibody (mAb),
bispecific antibody, tumor vaccine, immune checkpoint
blockade, cytokine-induced killer (CIKs), tumor-
infiltrating lymphocytes (TILs), and most recently
chimeric antigen receptor T (CAR-T) [1]. Application of
monoclonal antibodies (Herceptin, cetuximab) in malig-
nant tumor patients showed a satisfying response rate.
Immune checkpoint blockades are emerging immuno-
therapies against tumors. Pembrolizumab, nivolumab
(anti-PD-1mAb), and ipilimumab (anti-CTLA-4mAb),
which are representative immune checkpoint blocking
agent, have been approved by the Food and Drug Ad-
ministration (FDA) for melanoma patients, as either ini-
tial therapy or after relapse [2]. The CAR-T-based
immunotherapy has achieved significant progress in ma-
lignant hematological diseases. CARs are synthetic re-
ceptors consisting of extracellular single-chain variable
fragment (scFv), transmembrane domain, and
intracellular part of immunoreceptor tyrosine-based ac-
tivation motifs (ITAMs) and co-stimulatory signal (Fig. 1)
[3]. The scFv is responsible for recognizing and binding
to tumor-associated antigens (TAAs) expressed on the
tumor cell surface. The endodomain plays a pivotal role
in T cell activation, proliferation, persistence, and cyto-
toxicity. The structure of CAR is similar to T cell recep-
tor (TCR), but the scFv of CAR recognizes TAAs
independent of major histocompatibility complex
(MHC) and targets a variety of antigens expressed on
the surface of the tumor cell, including proteins, carbo-
hydrates, and gangliosides (Fig. 1) [4, 5]. The first gener-
ation of CARs merely includes activation signal CD3
zeta chain (CD3ζ) or Fc receptor γ (FcRγ) in intracellular
motif, thus inducing transient T cell activation [6]. The
second and third generation of CARs including one acti-
vation domain and one or more costimulatory domains
(CD28, 4-1BB, or OX40) were developed and contrib-
uted to the expansion, prolonged antitumor activity, and
cytokine secretion (such as IL-2, TNFα, and IFN-γ) of T
cell (Fig. 1) [7, 8]. Currently, anti-CD19 CAR-T cells
were demonstrated to be effective in the treatment of B
cell non-Hodgkin lymphoma (NHL), acute lympho-
blastic leukemia (ALL), and chronic lymphocytic
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leukemia (CLL) [9–13]. Anti-CD116 has been developed
for treating myelomonocytic leukemia [14].
Adoptive cellular therapy (ACT) using CAR-T cells is
also a novel way for the treatment of other malignant tu-
mors [15]. In solid tumors, epidermal growth factor re-
ceptor (EGFR), human epidermal growth factor
receptor2 (HER2), carcinoembryonic antigen (CEA), dis-
ialoganglioside 2 (GD2), mesothelin, prostate-specific
membrane antigen (PSMA), and interleukin-13Ra2
(IL13Ra2) are known as the targets of CAR-T cells. We
summarized the current CAR-T cell-targeted antigens in
Table 1. In this review, we mainly introduced the corre-
lated studies of EGFR, HER2, and mesothelin-specific
CAR-T cells. Those TAAs are commonly expressed on
solid tumors and have been developed by multi-research
institutes. More importantly, some studies have achieved
promising outcome.
Antitumor mechanism of CAR-T cells
CAR-T cells recognize specific tumor antigens in a
MHC-independent manner, which lead to the activation
and execution of its antitumor function [16]. Once CAR
specifically binds with TAAs, T cells are activated
through the phosphorylation of immune receptor
tyrosine-based activation motifs (ITAMs) and subse-
quently induce cytokine secretion, T cell proliferation,
and cytotoxicity [17]. The original T cells, including CD8
+ and CD4+ T cells, are isolated from peripheral blood
or tumor tissues of patients. It is generally agreed that
CD8+ T cells play a critical part in immune responses
against tumors, and CD4+ T cells can help to enhance
the efficiency of CD8+ T cell-mediated cytotoxicity [18].
Chimeric immunoreceptor-activated T lymphocytes per-
form cytotoxicity through two predominant pathways:
(1) secretion of perforin and granzyme granules and (2)
activation of death receptor signaling via Fas/Fas-ligand
(Fas-L) or TNF/TNF-R. CD8+ T cells kill tumor cells
through those two pathways. CD4+ T cells destroy target
cells primarily via perforin/granzyme, while death
receptor-mediated apoptosis is believed to function as a
compensatory pathway [19, 20]. Many strategies have
been employed to potentiate the functions of CAR-T
cells. It has been demonstrated that CAR-T cells with
multiple signaling receptors could improve amplifica-
tion, cytokine production, and cytotoxicity of T cells, as
well as reduce antigen-induced cell death (AICD) in
vitro and in vivo [21]. CD40L-modified T cells enhanced
the proliferation and secretion of proinflammatory Th1
cytokines, including IL-2, IFN-γ, IL-12, and TNF [22].
CD28 costimulation was critical for antigen-specific
cytokine secretion and T cell proliferation without obvi-
ous effect on the receptor-mediated target cell lysis [23].
IL-12 enhanced the activation of cytotoxic T cell [24], re-
cruited and reinforced the functions of innate immune
cells such as NK cell and macrophage [25], enhanced
the Th1-type helper T cell response, and exhibited anti-
angiogenic activities [26]. On this basis, T cells redir-
ected for universal cytokine killing (TRUCK) was
developed. TRUCK is a way to redirect CAR-T cells by
producing and releasing a transgenic product, such as
IL-12, to activate innate immune response against tumor
cells which are invisible to CAR-T cells [4]. Besides
Fig. 1 The structure of TCR and the three generations of CAR. T cell receptor (TCR) includes antigen-binding domain, transmembrane domain (TM do-
main), and immune receptor tyrosine-based activation motifs (ITAMs). The binding domain of CAR consists of a scFv, comprising the light (VL) and heavy
(VH) variable fragments of a TAA-specific monoclonal antibody joined by a flexible linker. The intracellular parts are different between the three generations
of CAR. The first-generation CAR only has the signal transduction domain of the CD3-zeta chain (CD3ζ) or Fc receptor γ (FcRγ) which mediated transient
persistence, inefficient cytotoxicity, and low-level cytokine secretion. The second and third generation CAR add one or more co-stimulatory domains
(CD28, 4-1BB, or OX40) to the first generation, which lead to the enhanced cytotoxicity and cytokine secretion along with prolonged T cell persistence
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targeting antigen-specific tumor cell, IFN-γ secreted by
CAR-T cells contributed to the antigen-independent de-
struction of tumor cell through IFNγR expressed in
tumor stroma [27]. Neeson et al. developed a novel
transgenic mouse model CAR OT-I. CAR OT-I cells not
only recognized target tumor cells and secreted cyto-
toxic granule proteins (perforin, granzyme B) but also
induced serial killing which were observed in real time
via time-lapse microscopy [28]. In addition, the outcome
of clinical application of CAR T cells could be improved
by strengthening the function of CAR-T cells through
co-activation of macrophage and NK cell (Fig. 2).
Target antigen expressing on solid tumor cell
surface
In this part, we summarized the preclinical and clinical
studies of CAR-T antigens in solid tumors, focusing on
the common targets of EGFR, HER2, and mesothelin.
Emphases were put on the scientific basic and progress
in preclinical experiments of CAR-T cells.
EGFR
EGFR is a 170-KDa transmembrane receptor tyrosine
kinase belonging to the ErbB (also known as HER) onco-
gene family [29–31]. EGFR is expressed in the skin,
gastrointestinal system, kidney, and other normal tissues
at the physiological level; however, it is aberrantly acti-
vated in many epithelial tumors, such as lung cancer,
pancreatic cancer, colorectal cancer, breast cancer, and
head and neck squamous cell carcinoma (HNSCC) [32,
33]. EGFR plays central roles in regulation of cellular
multiplication, differentiation, and metastasis, and the
overexpression of EGFR is related to a more aggressive
clinical progression and poor prognosis [34, 35]. In fact,
EGFR has been a therapy target for many years. Cur-
rently, targeted-EGFR antitumor agent is mainly divided
into two categories: anti-EGFR monoclonal antibodies
(mAbs) and small-molecule tyrosine kinase inhibitors
(TKIs) [36]. Anti-EGFR mAbs prevent the EGF binding
and receptor activation by occupying the ligand-binding
site of the EGFR. TKIs inhibit autophosphorylation and
downstream intracellular signaling of EGFR [37]. Two
mAbs (cetuximab and panitumumab) and two TKIs (ge-
fitinib and erlotinib), as first-generation EGFR inhibitors,
have been used for the treatment of NSCLC, pancreatic
cancer, HNSCC, renal cancer, and colorectal cancer
(CRC) [38]. Nevertheless, the therapeutic efficacy of the
EGFR inhibitors was attenuated in some patients, result-
ing from EGFR mutations and the acquired drug resist-
ance. Hence, to create novel therapeutic strategies to
overcome the defects is imperative [39, 40]. Anti-EGFR
CAR-T therapy is an alternative strategy for EGFR over-
expression malignant cancers, although the application
of CAR-T therapy toward solid tumors remains challen-
ging [41]. The most common oncogenic EGFR mutant is
the type III EGFR (EGFRvIII), which results in an in-
frame deletion of exons 2 to 7 [42, 43]. EGFRvIII ap-
pears to meet most of the criteria of ideal antigen for
CAR-T therapy, for it is the most commonly altered
form of EGFR in cancers with no expression in normal
tissues [44]. Expression of EGFRvIII promotes tumor cell
growth, invasion, migration, and therapeutic resistance
and is associated with poor long-term survival [45, 46].
Preclinical studies on EGFR-specific CAR-T cells
Glioblastoma (GBM) remains one of the deadliest pri-
mary brain tumors in adults, and standard treatments
for GBM do not significantly increase the survival time.
EGFRvIII is expressed in GBM cell surface; therefore,
CAR-T cell targeting EGFRvIII is a novel strategy worth
studying [47]. Morgan et al. conducted a series of exper-
iments to construct competent CARs and evaluated the
ability of CAR-engineered T cells recognizing EGFRvIII.
Considering that the established cell lines may not keep
the molecular characteristics of primary human cancers,
Table 1 Tumor-associated antigens of CAR-T cell target
Antigen Full name Disease




EGFRvIII Variant III of the epidermal
growth factor receptor
Glioblastoma
HER2 Human epidermal growth
factor receptor 2
Ovarian cancer, breast cancer,
glioblastoma, colon cancer,
osteosarcoma, medulloblastoma





CEA Carcinoembryonic antigen Pancreatic adenocarcinoma,
breast cancer, colorectal
carcinoma
GD2 Disialoganglioside 2 Neuroblastoma, melanoma
IL13Rα2 Interleukin-13Ra2 Glioma
GPC3 Glypican-3 Hepatocellular carcinoma
CAIX Carbonic anhydrase IX Renal cell carcinoma (RCC)
L1-CAM L1 cell adhesion molecule Neuroblastoma, melanoma,
ovarian adenocarcinoma
CA125 Cancer antigen 125 (also
known as MUC16)
Epithelial ovarian cancers
CD133 Cluster of differentiation








CTAG1B Cancer/testis antigen 1B
(also known as NY-ESO-1)
Melanoma and ovarian cancer
MUC1 Mucin 1 Seminal vesicle cancer
FR-α Folate receptor-α Ovarian cancer
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Morgan group selected the glioblastoma stem cells
(GSCs) expressing EGFRvIII as target cell lines. CAR
scFv derived from human mAb 139 recognized GSCs
expressing mutant EGFRvIII, but not human normal tis-
sues. T cell signaling transduction domain CD28-41BB-
CD3ζ (named 139-28BBZ) made CAR-T keep better sur-
vival comparing with the original CAR vector that used
CD28-CD3ζ (named 139-28Z) [48–50], but the bio-
logical activity and cytotoxicity were at the equal level.
The engineered T cells expressing CAR can specifically
recognize EGFRvIII+ cell lines, while no reactivity to co-
cultured normal tissue cells. At present, a phase I clin-
ical trial (NCT01454596) using anti-EGFRvIII CAR-T
cells is recruiting patients with recurrent glioblastoma
[51]. Study by Marcela et al. also evaluated the charac-
teristics of anti-EGFRvIII CAR-T cells and verified its an-
titumor activity against glioblastoma cells in vitro and
vivo [52]. The humanized anti-EGFRvIII CAR-T cells
produced IFN-γ, IL-2, TNF-α, and only lysed EGFRvIII-
expressing target cells. In order to confirm the
Fig. 2 Antitumor mechanism of CAR-T. a TCR recognizes TAAs depending on the MHC presentation. The advantage is that TCR could recognize
intracellular and extracellular antigens. While tumor cells often downregulate MHC expression to escape the killer T cells, b CAR-T cells can specifically
recognize the tumor antigens in a MHC-independent manner. And then, the T cells were activated through the phosphorylation of ITAMs followed by
enhanced cytokine (include IL-2, IL-4, IFN-γ, IL-12, and TNF) secretion, T cell proliferation, and cytotoxicity. IL-12 could recruit and reinforce the functions of
innate immune cells such as NK cell and macrophage. Activated T and CAR-T cells perform cytotoxicity mainly through secretion of perforin and granzyme
granules, also through the death receptor pathway such as Fas/Fas-L. Due to added co-stimulatory signal to endodomain, antitumor activity mediated by
CARs is stronger than TCRs
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antitumor activity in vivo, U87-EGFRvIII tumors were
implanted subcutaneously and intracranially into NSG
mice, respectively. The results indicated that CAR-T-
EGFRvIII cells controlled tumor growth and increased
median survival time. This group also used mice grafted
with normal human skin to test the potential toxicities
of anti-EGFRvIII CAR-T cells, and the results of skin
graft assay demonstrated that no significant lymphocytic
infiltrate by immunohistochemistry. On this basis, Mar-
cela group started a phase 1 clinical trial
(NCT02209376) of EGFRvIII-specific CAR-T cells in pa-
tients with either residual or recurrent glioblastoma [53].
D-270MG is a tumor cell line that naturally expresses
EGFRvIII [54]. Sampson et al. established the D-
270MGFLuc/GFP subline that co-expressed firefly lucifer-
ase (FLuc) and GFP as the target of EGFR-specific CAR-
T cells. The study results demonstrated that anti-
EGFRvIII CAR-T cells effectively transpassed the blood-
brain barrier (BBB) to arrive at invasive GBM tumors
and mediated tumor regression and prolonged survival
in NSG mice [55]. Zuo et al. used the EGFR-positive
(EGFR+) cells including A549, NCI-H1299, NCI-H460,
SGC7901, HT29, and EGFR-knockdown (EGFR−) cells
including A549-EGFR−, SGC7901-EGFR−, and HT-29-
EGFR− to investigate the antitumor activity of EGFR-
specific CAR-CIK cells. The study reported that EGFR-
specific CAR observably potentiated cytotoxicity and in-
duced secretion of IFN-γ and IL-2 in EGFR-positive cell
lines and xenograft tumor models, but not in EGFR
negative ones [56]. In summary, the preclinical studies
of EGFR-specific CAR-T cells exhibited potent antitumor
effect in vitro and in vivo.
Clinical trials on EGFR-specific CAR-T cells
Multicenter clinical trials using CAR-T cells targeting
EGFR or EGFRvIII are underway. We summarized these
clinical trials in Table 2. A phase I trial by Han et al.
studied the EGFR-targeted CAR-T cells in 11 patients
with EGFR-expressing advanced relapsed/refractory
NSCLC (NCT01869166). In this study, the six female
and five male patients were divided into three cohorts:
in cohort 1, EGFR-CAR T cells infused into four patients
directly without any conditioning regimens; in cohort 2,
two patients were conditioned with cyclophosphamide,
followed by CAR-T EGFR therapy; and in cohort 3, two
patients were conditioned by cyclophosphamide, peme-
trexed, and cisplatin and three were conditioned by
cyclophosphamide, docetaxel, and cisplatin, respectively.
All patients received EGFR-targeted CAR-T cell infu-
sions at dose ranged from 0.45 to 1.09 × 107 cells/kg. Of
11 patients, there were two persons acquired PR and five
kept stable disease (SD). The anti-EGFR CAR-T cells se-
creted cytokines including IL-2, IL-4, IL-6, IFN-γ, TNF-
α, GM-CSF, and granzyme B in co-culture with EGFR-
positive tumor cells. However, after the infusion of
EGFR-specific CAR-T cells, the serum levels of cytokines
observed at different time point were less obvious com-
pared with the experiment in vitro. Investigators moni-
tored the copy numbers of CAR-EGFR transgene in
peripheral blood (seven patients) and tumor tissues (four
patients) by quantitative real-time PCR. In peripheral
blood, the copy numbers of CAR-EGFR transgene hold
high level for more than 4 weeks. CAR-EGFR transgene
specifically accumulated in tumor tissues. The only tol-
erable and controllable toxicities reported in the study
were skin toxicity, nausea, vomiting, dyspnea, and
hypotension, and there was no cytokine storm observed.
Therefore, the CAR-T-EGFR cells were found to be feas-
ible and safe in patients of relapsed/refractory NSCLC
[57].
HER2
HER2 is a 185-KDa transmembrane glycoprotein which
also belongs to the family of the EGFR [58, 59]. HER2
gene amplification or HER2 overexpression plays a cru-
cial role in the biologic behavior and pathogenesis of
some type of human cancers [60]. HER2 is overex-
pressed in 25–30% of breast and ovarian cancers [61],
up to 60% of human osteosarcomas (OS) [62], approxi-
mately 80% of GBM [63], and 40% of medulloblastomas
but is not detected in normal cerebellum and other
brain tissues [64]. Overexpression of HER2 is associated
with cellular transformation and carcinogenesis and also
correlated with poor clinical outcome [65, 66]. On this
basis, HER2 monoclonal antibody trastuzumab (Hercep-
tin) was first approved for use in patients with HER2-
overpressed breast cancer. Trastuzumab alone or in
combination with chemotherapy prolongs survival in
both primary and metastatic breast cancer [67]. At
present, the clinical trials about HER2 tyrosine kinase in-
hibitors such as lapatinib and neratinib are still ongoing
[68]. However, many tumors such as osteosarcoma, glio-
blastoma, and medulloblastoma expressing HER2 at low
levels are ineffectively recognized by trastuzumab [66].
In addition, approximately half of those patients either
do not respond to these therapies or develop secondary
resistance which results to treatment failure [69, 70].
Therefore, it is necessary to create novel therapeutic ap-
proach to treat these patients.
Preclinical studies on HER2-specific CAR-T cells
In GBMs, CD133-positive stem cells keep higher expres-
sion of HER2 than CD133-negative counterparts. A
study result indicated that HER2-specific CAR-T cells
targeted and killed autologous HER2-positive GBMs in
vitro and facilitated regression of GBMs in an orthotopic
xenograft model [71]. Sun et al. constructed a human-
ized HER2 CAR-T cell containing chA21scFv and
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Table 2 Clinical trials of CAR-T cells
Target Identifier Institution Phase Status Disease Comments
EGFR NCT02331693 Shanghai Cancer Institute I Recruiting Glioma Autologous T cells transduced with a lentiviral
vector
EGFRvIII NCT02844062 Beijing Sanbo Brain
Hospital
I Recruiting Glioma Lymphodepletion chemotherapy, followed by CAR-
T
EGFRvIII NCT01454596 National Cancer Institute
(NCI)
I/II Recruiting Glioma Autologous T cells, a retroviral vector
EGFRvIII NCT02209376 University of Pennsylvania/
University of California
I Recruiting Glioma Autologous T cells, a lentiviral vector




Glioma Dose escalation cohorts for 4 dose levels
EGFR NCT01869166 Chinese PLA General
Hospital
I/II Completed NSCLC Safe and feasible
HER2 NCT02713984 Southwest Hospital, China I/II Recruiting HER2-positive cancer
HER2 NCT01935843 Chinese PLA General
Hospital
I/II Recruiting HER2-positive cancer
HER2 NCT02547961 Fuda Cancer Hospital
Guangzhou
I/II Recruiting Breast cancer A retrovirus vector, preconditioning treatment
HER2 NCT02442297 Baylor College of Medicine I Recruiting Glioma Intracranial injection
HER2 NCT01109095 Baylor College of Medicine I Active, not
recruiting
Glioma CMV-specific cytotoxic T cells (CMV-T cells)
HER2 NCT00889954 Baylor College of Medicine I Active, not
recruiting
HER2-positive cancer TGFBeta resistant HER2/EBV-CTLs




Results is not encouraging
HER2 NCT00902044 Baylor College of Medicine I/II Completed HER2-positive
sarcoma
Safe and feasible





MSLN NCT02706782 Shanghai Renji Hospital I Recruiting Pancreatic cancer Transcatheter arterial infusion










Premedicated with acetaminophen and
diphenhydramine, and administered
cyclophosphamide
MSLN NCT02465983 University of Pennsylvania I Active not
recruiting
Pancreatic cancer Combination therapy with CART-meso cells and
CART19 cells
MSLN NCT02959151 Shanghai Tumor Hospital I/II Recruiting Pancreatic cancer Combined with interventional therapy





MSLN NCT01355965 University of Pennsylvania I Completed Pleural mesothelioma Safe and feasible
MSLN NCT02414269 Memorial Sloan Kettering
Cancer Center
I Recruiting Malignant pleural
disease
With/without chemotherapy










Transfected with chimeric anti-mesothelin immu-
noreceptor SS1
IL13Rα2 NCT00730613 City of Hope Medical
Center
I Completed Glioblastoma Safe and feasible
IL13Rα2 NCT02208362 City of Hope Medical
Center
I Completed Glioblastoma Safe and feasible
CEA NCT01373047 Roger Williams Medical
Center
I Completed Liver metastases Safe and feasible
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examined its antitumor activity. The results indicated
that chA21-28z HER2-specific CAR-T cells recognized
and killed HER2+ breast and ovarian cancer cells in
vitro. Simultaneously, abundant IFN-γ and IL-2 secre-
tion were also detected. In xenograft model, the HER2-
specific CAR-T cells also significantly restricted tumor
growth [72]. Another study demonstrated that oligoclo-
nal camelid single-domain antibodies (VHHs) could tar-
get a range of different epitopes on HER2 antigen. Based
on the potent targeting ability of oligoclonal VHHs, the
oligoclonal VHHHER2-CAR-engineered Jurkat T cells ex-
hibited higher expansion, cytokine secretion, and cyto-
toxicity when exposed to HER2-expressing cells [73]. To
reduce antigen escape, Hegdeet et al. created a bispecific
CAR molecule co-targeting the two glioma-associated
antigens, HER2 and IL-13Rα2, and expanded the CAR-T
cells expressing tandem CARs (TanCAR). Encouragingly,
the TanCAR effectively redirected T cells to the two anti-
gens and enhanced the function of CAR-T cells and the
secretion of cytokines in vitro and in vivo. Therefore, the
TanCAR-T cell agents were considered as a potential
therapeutic method to control tumor growth as this
study reported [74, 75]. Recently, a group combined bis-
pecific antibody αHER2/CD3 and CAR-T therapy. Their
data indicated that αHER2/CD3 RNA-engineered T cells
exhibited antitumor activity in HER2+ N87 tumor cells
and in N87 tumor-bearing mice. Moreover, bystander T
cells also showed the similar effects. This new strategy
may be a potential therapeutic approach for HER2+ ma-
lignancies [76]. To promote the transduction efficiency,
EBV-CTLs were modified to express HER2-CAR via the
nonviral piggyBac (PB) transposon which had high gene-
transfer efficiency and large coding capacity. PB-
modified HER2-CTLs could specifically target and kill
HER2-positive tumor cells in vivo and suppress tumor
growth in xenogeneic murine models [77]. Although
60% human osteosarcoma expressed HER2 [62, 78], a
low level of HER2 renders monoclonal antibodies to
HER2 ineffective. Hence, a group used genetic-modified
T cell targeting HER2 to determine the antitumor activ-
ity in osteosarcoma. The HER2-specific CAR-T cells pro-
liferated, produced cytokines, and killed tumor cells
after exposure to HER2-positive osteosarcoma cell lines
in vitro. Moreover, they created two mouse models: one
is locoregional disease in a severe combined immune de-
ficiency (SCID) mouse model and the other is lung me-
tastases model. Adoptive transfer of HER2-specific
CAR-T cells caused osteosarcoma regression at the dif-
ferent sites [79]. Similarly, HER2-specific CAR-T cells
had the capacity of recognizing and killing HER2-
positive medulloblastoma cells in vitro and induced re-
gression of tumors in an orthotopic xenogeneic SCID
model [64]. These preclinical studies have achieved en-
couraging results, promoting HER2-specific CAR-T clin-
ical trials to test the feasibility and safety.
Clinical trials on HER2-specific CAR-T cells
At present, Southwest Hospital in China, Chinese
PLA General Hospital, Fuda Cancer Hospital
Guangzhou, and Baylor College of Medicine are car-
rying out clinical trials of HER2-specific CAR-T cells.
We summarized these clinical trials in Table 2. Phase
I/II clinical study (NCT00924287) sponsored by Na-
tional Cancer Institute (NCI) has completed. This
trial was designed to evaluate the safety and efficacy
of HER2-specific CAR-T cells in patients with re-
lapsed/refractory HER2-positive sarcoma. Nineteen
patients received escalating doses (range 1 × 104/m2 to
1 × 108/m2) of HER2-specific CAR-T cells including
eight dose levels. The study reported that among the
detected serum cytokines, only the concentration of
IL-8 had significantly increased within 1 week after
infusion and persisted for up to 4 weeks. Although
HER2-specific CAR-T cells had no expansion after in-
fusion in the peripheral blood, these cells could traffic
to tumor sites and maintain at low levels for more
than 6 weeks. T cell persistence and copy number
were correlated with the infused T cell dose. The
clinical benefit of HER2-specific CAR-T cell was not
encouraging, only four of nineteen patients acquired
stable disease (SD). In the process of HER2-specific
CAR-T cell infusion, dose-limiting toxicity was not
observed apart from a patient with the highest dose
levels within 12 h post-infusion [80].
Table 2 Clinical trials of CAR-T cells (Continued)
FAP NCT01722149 University of Zurich I Recruiting Malignant pleural
mesothelioma
Followed lymphodepletion
GD2 NCT00085930 Baylor College of Medicine I Completed Neuroblastoma Safe and feasible











Relapsed and/or chemotherapy refractory
advanced malignancies
The details of Table 2 derived from http://clinicaltrials.gov/
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Mesothelin
Mesothelin (MSLN) is a 40-KDa cell surface tumor dif-
ferentiation antigen, which derived from the 69-KDa
precursor protein encoded by Mesothelin gene [81, 82].
The normal biological function of mesothelin almost re-
mains unknown. Some studies suggest that mesothelin is
the receptor of CA125/MUC16, and the interaction be-
tween mesothelin-CA125 mediates cell adhesion and
may be a critical point in the metastatic of ovarian can-
cer [83, 84]. Mesothelin overexpression promotes tumor
cell proliferation and regional invasion and is associated
with poor prognosis, such as worse recurrence-free sur-
vival (RFS) and overall survival (OS) [85–87]. As a
tumor marker, soluble mesothelin in serum plays an im-
portant role in diagnosing and monitoring therapeutic
effect for patients with malignant pleural mesothelioma
(MPM) and ovarian cancer [88–91]. Mesothelin is
expressed at low levels in normal tissues, including
pleura, pericardium, peritoneum, tunica vaginalis [92–
94], but it is overexpressed in various malignancies in-
cluding MPM, ovarian cancers, pancreatic cancers, and
non-small cell lung cancers [95–98]. Due to the weak
expression in normal tissues and strong expression in
several cancers, mesothelin is considered as an attractive
target for immune-based therapies [81]. With respect to
mesothelin-targeted therapies such as anti-mesothelin
recombinant immunotoxin SS1P, chimeric anti-
mesothelin monoclonal antibody MORAb-009, and
mesothelin cancer vaccines CRS-207, investigators per-
formed a lot of preclinical researches and opened a
series of clinical trials [99–102]. Simultaneously, a num-
ber of studies about CAR-T cells targeting mesothelin
are in progress.
Preclinical studies on MSLN-specific CAR-T cells
June et al. demonstrated that the mesothelin-specific T
cells exhibit antitumor effects on large pre-established
mesothelioma xenografts in NOD/scid/IL2rγ−/− mice.
Their data suggested that the combination of CD137
and CD28 improved multifunctional cytokine secretion
and enhanced the function of CAR T cells in tumor-
bearing mice [103]. In the tumor microenvironment,
some inhibitors hampered the function of CAR T cells.
For example, diacylglycerol kinase (dgk), as a negative
regulator of TCR signaling, is expressed in T cells. Its
isoform includes dgkα and dgkζ. Previous studies found
that deletion of either dgk isoform induced the activa-
tion of DAG-mediated Ras/ERK pathway and prolifera-
tion of T cells [104–106]. Based on this, Koretzky et al.
demonstrated that deletion of dgks greatly enhanced ac-
tivity against tumor and improved persistence of CAR-
engineered T cells targeting mesothelin in vitro and in
implanted tumors. Beyond that, pharmacologic inhib-
ition of dgks also facilitated function of mesothelin-
specific CAR-T cells. Moreover, dgk-deficient T cells
showed decreased sensitivity to TGFβ and increased
FasL and TRAIL expression. Such a combined thera-
peutic approach might be translated clinically as the
study reported [107]. Moon et al. found that a single
intravenous injection of human mesoCAR-T cells into
immunodeficient mice significantly restrained the tumor
growth but did not cure tumor. They considered that
upregulation of inhibitory receptors was the main cause
of mesoCAR-T cell hypofunction [108]. As an inhibitor
within the tumor microenvironment, upregulation of
PD-1 limited T cell function [109]. Cherkassky et al.
found that PD-1 antibody could reverse PD-1-mediated
CAR-T cell exhaustion and mesoCAR-T cells also
showed delayed exhaustion upon repeated antigen
stimulation. Hence, combination of costimulation and
cell-intrinsic PD-1 checkpoint blockade could overcome
inhibitory effect on CAR-T cells in MSLN-expressing
tumor microenvironment [110]. CAR-T therapy
achieved good results in preclinical studies. But the ef-
fect was not satisfied in the clinical trials mainly due to
its adverse effects. For example, scFv was generally de-
rived from murine monoclonal antibodies; the induction
of human anti-mouse antibody (HAMA) might shorten
T cell survival time [111]. A study demonstrated that
fully human mesothelin-specific CAR-T cells showed po-
tent cytolytic activity toward mesothelin-positive tumor
cells and controlled large, well-established ovarian can-
cer growth in a xenogeneic mouse model. Besides,
mesothelin-specific CAR-T cells induced bystander kill-
ing of mesothelin-negative tumor cells [112]. On-target/
off-tumor toxicity could cause life-threatening adverse
effects in the application of CAR-T cells, because the tar-
get antigen also expressed on normal cell surface at low
levels. Both a-folate receptor (FRa) (90%) and mesothelin
(70%) were overexpressed in ovarian cancers [113, 114],
and their expression pattern on normal tissues is mainly
non-overlapping. Based on the foundation of above stud-
ies, Daniel et al. generated trans-signaling CAR T cells
engineered to co-express anti-mesoscFv-CD3 and anti-
FRascFv-CD28CARs, aiming to diminish the potential
toxicity of CAR-T cells to normal tissue cells expressing
low levels of TAAs. The result indicated that trans-
signaling CAR-T cells exhibited higher antitumor poten-
tial in vitro and in vivo. Moreover, trans-signaling CAR-
T cells were resistant to antigen-induced cell death
(AICD) [115]. The successes achieved by CAR-T cells in
hematological malignancies were unable to be accom-
plished in solid tumor, partly owing to the low efficacy
of CAR-T cells homing to tumor sites. Stimulating more
chemokine receptors expressed on CAR-T cells or direct
regional injection may be valid. Chemokine CCL2 is
highly expressed by MPM tumors, but the expression
level of CCL2 receptor CCR2 on resting and activated T
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cells is low. Therefore, Moon et al. transduced the che-
mokine receptor CCR2b into mesoCAR-T cells to po-
tentiate trafficking of CAR-T cells into tumors. Their
study demonstrated that the functional CCR2b in the
mesoCAR-T cells significantly increased the number of
intratumoral T cells and improved antitumor efficacy in
vitro and in vivo [116]. Adusumilli et al. found that com-
pared with intravenous injection, intrapleural adminis-
tration of anti-mesothelin CAR-T cells exhibited greater
antitumor potency and strongly promoted the expan-
sion, differentiation, and persistence of T cells [117].
Clinical trials on MSLN-specific CAR-T cells
Many clinical trials about mesothelin-specific CAR-T
cells are ongoing. We summarized these clinical trials in
Table 2. Marcela et al. started a clinical study in four pa-
tients infused with autologous T cells transducted with
mRNA to express CAR derived from a murine antibody
to human mesothelin. These results demonstrated that
when patients received intermittent infusion of meso-
RNA CAR-T cells, the serum IgE levels detected via
ELISA assay were elevated which caused anaphylaxis.
Therefore, they suggested that a single infusion of stably
transducted, long-lived CAR-T cells or constructing
CAR based on the humanized antibodies may be safer
and more effect [52]. The phase I clinical trial
(NCT01355965) conducted by Beatty et al. was designed
to improve the feasibility and safety of mRNA-
transduced CAR-T cells targeting mesothelin (meso-
CAR-T cells) in patients with advanced MPM. They pre-
sented two case reports indicating that mRNA CAR-T
cells showed potent antitumor activity without evident
on-target/off-tumor toxicity against normal tissues, infil-
trated solid tumor tissues, and induced humoral epitope
spreading after infusion [118].
Other target antigens
In addition, there are lots of tumor-associated antigens
studied by investigators in solid tumors. CA125 also
called MUC16 is a well-known ovarian tumor antigen
routinely used for monitoring disease. To enhance the
antitumor efficacy, Brentjens et al. developed T cells co-
expressing MUC16 CAR and IL-12, and the results were
as expected both in vitro and in vivo [119]. Based on the
rationale, they opened a phase I clinical trial in patients
with recurrent ovarian cancer [120]. Carbonic anhydrase
IX (CAIX) is an attractive target antigen because it is
overexpressed in renal cell carcinoma (RCC) but is not
found on normal kidney tissue. The CAIX-specific CAR-
T cells inhibited tumor growth in xenograft model [121].
Several malignant tumors including pancreatic adeno-
carcinoma, breast cancer, and colorectal carcinoma over-
expressed carcinoembryonic antigen (CEA). Guest et al.
generated CAR-T cells for the phase I/II clinical trial of
CEA-specific CAR-T therapy in 14 patients with ad-
vanced CEA+ malignancy [122]. At present, clinical tri-
als of anti-CEA CAR-T cells in Advanced Liver
Malignancy (NCT02959151) and CAR-T Cells Targeting
CEA Positive Cancer (NCT02349724) are ongoing.
Neuroblastoma is a high-risk extracranial malignant
tumor of childhood. Disialoganglioside (GD2) is overex-
pressed in almost all neuroblastoma. Therefore, GD2 is
an ideal candidate of CAR-T cells. The preclinical and
clinical studies of GD2-specific CAR-T cells have
achieved some progress [123, 124]. Moreover, the clin-
ical trial of GD2-specific CAR-T therapy in 19 patients
with advanced neuroblastoma has completed by Louis et
al. It was showed that eight achieved remission and 11
with active disease [125]. A study reported that the
GD2-specific CAR-T cells showed anti-melanoma activ-
ity in vitro and in vivo [126]. Similar to GD2, L1 cell ad-
hesion molecule (L1-CAM) is also overexpressed in
neuroblastoma. In addition, ovarian adenocarcinoma,
medulloblastoma, and melanoma all highly expressed
L1-CAM [127]. Investigators tested the antitumor effi-
cacy and safety in preclinical and clinical studies [128–
130]. Glypican 3 (GPC3) is highly expressed in hepato-
cellular carcinoma (HCC) and hepatoblastoma. Study re-
sults demonstrated that all GPC3-CAR-T cells showed
potent cytotoxicity to GPC3-positive cells [131]. Aiming
at GPC3 and asialoglycoprotein receptor1 (ASGR1) an-
other TAA in HCC, a group developed the dual-targeted
CAR-T cells. They found that dual-targeted CAR-T cells
caused higher proliferation, antitumor activity, and cyto-
kine secretion than signal-targeted CAR-T cells in vitro
[132]. Prostate-specific membrane antigen (PSMA) was
expressed in prostate cancer cells. PSMA-targeted CAR-
T cells exhibited superior antitumor efficacy in vitro. In
established models, PSMA-targeted CAR-T cells also ef-
fectively eliminated prostate cancer [133–135]. CD133,
as a specific molecular biomarker for CSCs, is an attract-
ive therapeutic target for CAR-T therapy [136, 137].
CD133-specific CAR-T cells in a patient with advanced
cholangiocarcinoma have shown antitumor activity
[138]. At present, a phase I clinical trial of anti-CD133
CAR-T cells in patients with relapsed and/or chemother-
apy refractory advanced malignancies is ongoing
(NCT02541370). In addition to above antigens, fibro-
blast activation protein (FAP) [139, 140], NY-ESO-1
[141], MUC1 [142], foliate receptor [143, 144], and
IL13Rα2 [145, 146] are also potential target antigens for
immunotherapy.
Conclusions
In this review, we summarized the current preclinical
and clinical studies on CAR-T therapy against solid tu-
mors, especially targeting EGFR, HER2, and MSLN. The
ideal target for CAR-T cells would be the tumor-specific
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antigens which are homogenously expressed on the sur-
face of malignant cell and play a critical role in tumori-
genesis. Although the curative effect in CAR-T
treatments of hematological malignancies are reported,
the results of pilot clinical trials on solid cancers are
below expectation. Several obstacles have remained to
be overcome for a successful application of CAR-T cells
in solid tumor, including the lack of ideal TAAs, ineffi-
cient trafficking of CAR-T cells to tumor sites, hostile
solid tumor microenvironment, and the risk of develop-
ing on-target/off-tumor toxicities [15, 17]. To solve the
problems, investigators have developed some strategies
to potentiate the trafficking of CAR-T cells [116], reduce
the inhabitation effect of tumor microenvironment
[110], decrease the adverse effects, and so on [115]. In
general, the preclinical studies of CAR-T cells in vitro
and in vivo showed potent antitumor efficacy; with fur-
ther exploration to improve the feasibility, safety, and ef-
ficiency of CAR-T cells, CAR-T therapy will take the
central stage in the treatment of solid tumors.
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